Esperion
Ann Arbor
About Esperion
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $1.2B
- Funding stage: M&A
- Last round: Post-IPO Debt (Mar 2026)
- Ticker: nasdaq:ESPR
- Website: esperion.com
- Phone: 734-332-0506
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/esperion-15229 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.